Holen Sie sich die Stockscreener-App
47.81
1.26%
0.575
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – DUS:S49 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Q3 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49) - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSE:0LB2) - TradingView
S49 Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
SUPN Forecast — Price Target — Prediction for 2027 - TradingView
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSX:A1JX3U) - TradingView
0LB2 Forecast — Price Target — Prediction for 2027 - TradingView
A1JX3U Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Price to earnings forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2 - TradingView
Enterprise value to revenue forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN - TradingView
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Supernus Pharmaceuticals Insiders Sold US$2.1m Of Shares Suggesting Hesitancy - 富途牛牛
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest - Yahoo Finance
How Strong Quarterly Results and MERGE Partnership Will Impact Supernus Pharmaceuticals (SUPN) Investors - Sahm
Supernus Investors Approve Directors, Pay and Incentive Plan - The Globe and Mail
Supernus Pharmaceuticals shareholders approve director elections and key proposals - Investing.com UK
Supernus Pharmaceuticals shareholders approve director elections and key proposals By Investing.com - Investing.com Nigeria
Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan - Stock Titan
Behavioral Patterns of SUPN and Institutional Flows - Stock Traders Daily
Supernus Pharmaceuticals Inc (SUPN) Institutional Confidence - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record By Investing.com - Investing.com South Africa
Supernus Pharmaceuticals Inc (SUPN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus Pharmaceuticals names MERGE as agency of record - Investing.com
Supernus Pharmaceuticals Inc - TradingKey
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record - The Manila Times
Supernus Pharmaceuticals Inc (SUPN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Supernus Pharmaceuticals Inc (SUPN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sage Therapeutics Inc Stock (US78433J1043): Quiet trading as investors await next catalysts after Su - AD HOC NEWS
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead - Yahoo! Finance Canada
(SUPN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
SUPN Stock Price, Quote & Chart - ChartMill
Supernus Pharmaceuticals (SUPN) Price Target Increased by 32.88% to 59.36 - MSN
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66 - Moomoo
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year - AOL.com
Supernus Pharmaceuticals Q1 2026 earnings preview - MSN
Why Supernus Pharmaceuticals Shares Surged - AOL.com
SUPNSupernus Pharmaceuticals Inc Stock Price and Quote - Finviz
Supernus Pharmaceuticals to present at June healthcare investor conferences - Pluang
Drugmaker Supernus heads to New York and Miami for June investor events - Stock Titan
Supernus Pharmaceuticals to Participate in June Investor Conferences - GlobeNewswire
How (SUPN) Movements Inform Risk Allocation Models - Stock Traders Daily
SUPN PE Ratio & Valuation, Is SUPN Overvalued - Intellectia AI
Supernus CVR Milestone Triggers Cash Outflow And Undervalued Stock Debate - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 2026 Earnings: Robust EPS Beat Overshadowed by Mild Share DeclinePeak Earnings Alert - lwvtexas.org
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment By Investing.com - Investing.com Australia
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Supernus Reaches Milestone, Triggers Contingent Value Rights Payment - TipRanks
According to a contingent value rights agreement, Supernus Pharmaceuticals Inc will pay Equiniti Trust Company $0.50 per share after achieving the first milestone. - Bitget
[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Three Growth Stocks Under Pressure: Supernus, RGA, and Black Stone MineralsNews and Statistics - IndexBox
0.71%
2.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):